**6. Patents**

Patent application no. a 2019 00668: Theodora-Venera Apostol, S, tefania-Felicia Bărbuceanu, Laura Ileana Socea, Ioana S, aramet, Constantin Drăghici, Valeria Rădulescu, Mariana-Carmen Chifiriuc, Luminit,a Gabriela Mărut,escu, Octavian Tudorel Olaru, and George Mihai Nit,ulescu, 4-Isopropyl-1,3-oxazol-5(4*H*)-one Derivatives Containing a Diaryl sulfonyl Substituent in Position 2 with Antimicrobial Action, published in RO-BOPI No. 9/2021, from 30 september 2021.

**Supplementary Materials:** The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/pr10091800/s1, Figure S1: The 1H NMR spectrum of 2-{4-[(4 bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5**; Figure S2: The 13C NMR spectrum of 2- {4-[(4-bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5**; Figure S3: The 2D HETCOR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5**; Figure S4: The 1H NMR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-4*H*-1,3-oxazol-5-one **6**; Figure S5: The 13C NMR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-4*H*-1,3-oxazol-5-one **6**; Figure S6: The 2D HETCOR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-4*H*-1,3 oxazol-5-one **6**; Figure S7: The 1H NMR spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a**; Figure S8: The 13C NMR spectrum of 4-[(4-bromophenyl)sulfonyl]- *N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a**; Figure S9: The 2D HETCOR spectrum of 4-[(4 bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a**; Figure S10: The 1H NMR spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-[3-methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b**; Figure S11: The 13C NMR spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-[3-methyl-1-oxo-1-(*p*-

tolyl)butan-2-yl]benzamide **7b**; Figure S12: The 2D COSY spectrum of 4-[(4-bromophenyl)sulfonyl]- *N*-[3-methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b**; Figure S13: The 2D HETCOR spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-[3-methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b**; Figure S14: The 1H NMR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-phenyl-1,3-oxazole **8a**; Figure S15: The 13C NMR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-phenyl-1,3-oxazole **8a**; Figure S16: The 2D HETCOR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4 isopropyl-5-phenyl-1,3-oxazole **8a**; Figure S17: The 1H NMR spectrum of 2-{4-[(4-bromophenyl) sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b**; Figure S18: The 13C NMR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b**; Figure S19: The 2D HETCOR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b**; Figure S20: The FTIR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5**; Figure S21: The FTIR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-4*H*-1,3 oxazol-5-one **6**; Figure S22: The FTIR spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a**; Figure S23: The FTIR spectrum of 4-[(4-bromophenyl)sulfonyl]- *N*-[3-methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b**; Figure S24: The FTIR spectrum of 2-{4-[(4 bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-phenyl-1,3-oxazole **8a**; Figure S25: The FTIR spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b**; Figure S26: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5** dissolved in methanol at ≈0.025 mM; Figure S27: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}- 4-isopropyl-4*H*-1,3-oxazol-5-one **6** dissolved in methanol at ≈0.025 mM; Figure S28: The UV/VIS spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a** dissolved in methanol at ≈0.025 mM; Figure S29: The UV/VIS spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-[3 methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b** dissolved in methanol at ≈0.025 mM; Figure S30: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-phenyl-1,3-oxazole **8a** dissolved in methanol at ≈0.025 mM; Figure S31: The UV/VIS spectrum of 2-{4-[(4-bromophenyl) sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b** dissolved in methanol at ≈ 0.025 mM; Figure S32: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]benzamido}-3-methylbutanoic acid **5** dissolved in acetonitrile at ≈ 0.015 mM; Figure S33: The UV/VIS spectrum of 2-{4-[(4-bromophenyl) sulfonyl]phenyl}-4-isopropyl-4*H*-1,3-oxazol-5-one **6** dissolved in acetonitrile at ≈0.015 mM; Figure S34: The UV/VIS spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a** dissolved in acetonitrile at ≈0.015 mM; Figure S35: The UV/VIS spectrum of 4-[(4-bromophenyl)sulfonyl]-*N*-[3-methyl-1-oxo-1-(*p*-tolyl)butan-2-yl]benzamide **7b** dissolved in acetonitrile at ≈0.015 mM; Figure S36: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}- 4-isopropyl-5-phenyl-1,3-oxazole **8a** dissolved in acetonitrile at ≈0.015 mM; Figure S37: The UV/VIS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b** dissolved in acetonitrile at ≈0.015 mM; Figure S38: The GC/MS spectrum of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}- 4-isopropyl-4*H*-1,3-oxazol-5-one **6**; Figure S39: The RP–HPLC chromatogram of 2-{4-[(4-bromophenyl) sulfonyl]benzamido}-3-methylbutanoic acid **5**; Figure S40: The RP–HPLC chromatogram of 2-{4- [(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-4*H*-1,3-oxazol-5-one **6**; Figure S41: The RP–HPLC chromatogram of 4-[(4-bromophenyl)sulfonyl]-*N*-(3-methyl-1-oxo-1-phenylbutan-2-yl)benzamide **7a**; Figure S42: The RP–HPLC chromatogram of 4-[(4-bromophenyl)sulfonyl]-*N*-[3-methyl-1-oxo-1-(*p*tolyl)butan-2-yl]benzamide **7b**; Figure S43: The RP–HPLC chromatogram of 2-{4-[(4-bromophenyl) sulfonyl]phenyl}-4-isopropyl-5-phenyl-1,3-oxazole **8a**; Figure S44: The RP–HPLC chromatogram of 2-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-isopropyl-5-(*p*-tolyl)-1,3-oxazole **8b**.

**Author Contributions:** Conceptualization, T.-V.A.; methodology, T.-V.A., M.C.C., L.-I.S., C.D., O.T.O., G.M.N., D.-C.V., L.G.M., E.M.P., G.S. and S.-F.B.; investigation, T.-V.A., M.C.C., L.-I.S., C.D., O.T.O., G.M.N., D.-C.V., L.G.M., E.M.P., G.S. and S.-F.B.; writing—original draft preparation, T.-V.A., M.C.C., L.-I.S., C.D., O.T.O., G.M.N., D.-C.V., L.G.M., E.M.P., G.S. and S.-F.B.; writing—review and editing, T.-V.A., M.C.C., C.D., O.T.O., G.M.N. and S.-F.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Publish Not Perish Grants at the "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest.
